AR062666A1 - Benzotriazoles como moduladores de quinasas - Google Patents
Benzotriazoles como moduladores de quinasasInfo
- Publication number
- AR062666A1 AR062666A1 ARP070103923A ARP070103923A AR062666A1 AR 062666 A1 AR062666 A1 AR 062666A1 AR P070103923 A ARP070103923 A AR P070103923A AR P070103923 A ARP070103923 A AR P070103923A AR 062666 A1 AR062666 A1 AR 062666A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- alkyl
- hydrogen
- nr8r9
- independently
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 19
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000005530 alkylenedioxy group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos, composicion farmacéutica en base al compuesto y uso de estos para preparar medicamentos. Reivindicacion 1: Un compuesto de la formula (1) o una sal farmacéuticamente aceptable del mismo, en la que R es alquilo inferior, hidroxi-alquilo inferior, o un resto elegido entre grupo de formulas (2), en los que cada Ra es con independencia H, alquilo inferior, OH o hidroxi-alquilo inferior; cada Rb es con independencia H, alquilo inferior, halogeno, nitro o halo-alquilo inferior; p es el numero 1, 2, 3 o 4; X es O, CR4R5, C(=O) o S(O)x; R1 es hidrogeno, halogeno, alquilo o NH2; cada uno de R3 es con independencia halogeno, -NO2, alquilo inferior, -CN, -OR7, -NR8R9, -C(O)-R7, -OC(O)-R7, -CF3, -CHF2, -SO2-R10, o dos de R3 forman alquileno-dioxi; R4 es hidrogeno, alquilo inferior, ciano, -(CH2)nOR7, -(CH2)nNR8R9, -(CH2)n-C(O)-NR8R9, -(CH2)n-OC(O)-NR8R9, -(CH2)n-C(O)-OR7; -NR7-SO2-R10, -(CH2)n-NR8-C(O)-R11 o -(CH2)n-NR8-C(O)-OR6; R5 es hidrogeno o alquilo; o R4 y R5 juntos forman alquileno-dioxi; R6 es hidrogeno, alquilo inferior, heteroalquilo, cicloalquilo, heterociclilalquilo o -NR8R9; R10 es alquilo, cicloalquilo, heterociclilalquilo o -NR8R9; R1 es alquilo, cicloalquilo, heterociclilalquilo o -NR8R9; R11 es alquilo, cicloalquilo, heteroalquilo o (heterociclil)alquilo; R2 y R7 son con independencia entre si hidrogeno o alquilo inferior; R8 es hidrogeno, alquilo inferior, o acilo; R9 es hidrogeno, alquilo inferior, heteroalquilo, arilo, heteroarilo, heterociclilo, cicloalquilo; o R8 y R9 junto con el átomo de nitrogeno al que están unidos forman un heterociclilo que contiene por lo menos un átomo de nitrogeno en el anillo, opcionalmente sustituido por OH, oxo, alquilo inferior, alcoxi inferior o acilo; cada uno de m y x es con independencia un numero entero de 0 a 2; Y es hidrogeno, -(CH2)n-OR7, -(CH2)n-C(O)-R7 o-(CH2)n-C(O)-OR7; cada uno de y y z es con independencia el numero 0 o 1; y n es un numero entero de 0 a 4.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84309006P | 2006-09-08 | 2006-09-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062666A1 true AR062666A1 (es) | 2008-11-26 |
Family
ID=38893293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103923A AR062666A1 (es) | 2006-09-08 | 2007-09-06 | Benzotriazoles como moduladores de quinasas |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8962622B2 (es) |
| EP (1) | EP2066319B1 (es) |
| JP (1) | JP5325783B2 (es) |
| KR (1) | KR101177729B1 (es) |
| CN (1) | CN101511359B (es) |
| AR (1) | AR062666A1 (es) |
| AT (1) | ATE543498T1 (es) |
| AU (1) | AU2007293917B2 (es) |
| BR (1) | BRPI0717035B8 (es) |
| CA (1) | CA2662998C (es) |
| CL (1) | CL2007002572A1 (es) |
| ES (1) | ES2378577T3 (es) |
| IL (1) | IL197015A (es) |
| MX (1) | MX2009002229A (es) |
| PE (1) | PE20080659A1 (es) |
| TW (1) | TW200819440A (es) |
| WO (1) | WO2008028860A1 (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040082509A1 (en) | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| US8183339B1 (en) | 1999-10-12 | 2012-05-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| US8080517B2 (en) | 2005-09-12 | 2011-12-20 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| EP2102194A1 (en) | 2006-12-08 | 2009-09-23 | F. Hoffmann-Roche AG | Substituted pyrimidines and their use as jnk modulators |
| CA2701275C (en) * | 2007-10-23 | 2016-06-21 | F. Hoffmann-La Roche Ag | Kinase inhibitors |
| WO2009138340A1 (en) * | 2008-05-16 | 2009-11-19 | F. Hoffmann-La Roche Ag | Inhibitors of jnk |
| WO2009143865A1 (en) * | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| WO2009143864A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
| WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| EP2401274B1 (en) | 2009-02-24 | 2014-10-22 | F. Hoffmann-La Roche AG | Imidazo[1,2-a]pyridines as jnk modulators |
| JP5784604B2 (ja) * | 2009-08-10 | 2015-09-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｊｎｋ阻害剤 |
| JP5916719B2 (ja) * | 2010-06-04 | 2016-05-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｊｎｋの阻害剤として有用な２−アミノ−ピリミジン誘導体 |
| EP2576559B1 (en) * | 2010-06-04 | 2015-03-04 | F.Hoffmann-La Roche Ag | Inhibitors of jnk |
| WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
| CA2807036C (en) | 2010-10-14 | 2018-01-16 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
| SG191974A1 (en) * | 2011-02-09 | 2013-08-30 | Lubrizol Corp | Asphaltene dispersant containing lubricating compositions |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
| ES2694829T3 (es) | 2013-02-25 | 2018-12-27 | Aurigene Discovery Technologies Limited | Derivados de benzotriazol trisustituido como inhibidores de dihidroorotato oxigenasa |
| EP3013353B1 (en) | 2013-06-26 | 2021-04-21 | Xigen Inflammation Ltd. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of cystitis |
| WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| HRP20190039T1 (hr) | 2014-04-04 | 2019-03-08 | Syros Pharmaceuticals, Inc. | Inhibitori ciklin-ovisne kinaze 7 (cdk7) |
| WO2015193281A1 (en) * | 2014-06-16 | 2015-12-23 | Allinky Biopharma | P38 and jnk mapk inhibitors for the treatment and prophylaxis of degenerative diseases of the nervous system |
| WO2017204626A1 (en) | 2016-05-24 | 2017-11-30 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Combination therapy - combined map2k4/map3k1 and mek/erk inhibition |
| WO2018029336A1 (en) | 2016-08-12 | 2018-02-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway. |
| CN108117523B (zh) * | 2016-11-29 | 2021-05-07 | 上海医药工业研究院 | 卤代尿嘧啶类化合物的制备方法 |
| US20180369206A1 (en) | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| CA3060390A1 (en) | 2017-04-24 | 2018-11-01 | Aurigene Discovery Technologies Limited | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
| AU2019223906B2 (en) | 2018-02-20 | 2024-11-21 | Les Laboratoires Servier | Methods of use for trisubstituted benzotriazole derivatives |
| EP4215244A4 (en) * | 2020-09-15 | 2025-02-26 | Mitsubishi Tanabe Pharma Corporation | Triazine compound salt, crystal form thereof, and production method therefor |
| CN114456126A (zh) * | 2022-02-26 | 2022-05-10 | 郑州萃智医药科技有限公司 | 一种化合物的合成方法 |
| CN115677595B (zh) * | 2022-10-26 | 2024-06-14 | 江苏睿实生物科技有限公司 | 一种2,4,5-三氯嘧啶的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6329380B1 (en) | 1999-06-30 | 2001-12-11 | Merck & Co., Inc. | SRC kinase inhibitor compounds |
| CA2383546A1 (en) | 1999-06-30 | 2001-01-04 | William H. Parsons | Src kinase inhibitor compounds |
| US20030004174A9 (en) | 2000-02-17 | 2003-01-02 | Armistead David M. | Kinase inhibitors |
| EP1554269A1 (en) | 2002-07-09 | 2005-07-20 | Vertex Pharmaceuticals Incorporated | Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities |
| GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| EP1758892B1 (en) | 2004-06-10 | 2012-10-17 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| WO2006038001A1 (en) | 2004-10-06 | 2006-04-13 | Celltech R & D Limited | Aminopyrimidine derivatives as jnk inhibitors |
| GB0500492D0 (en) * | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
| US20060281764A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Aminopyrimidines as kinase modulators |
| ES2336625T3 (es) | 2006-03-22 | 2010-04-14 | Vertex Pharmaceuticals Incorporated | Inhibidores de la proteina quinasa c-met para el tratamiento de trastornos proliferativos. |
-
2007
- 2007-08-30 CN CN2007800334496A patent/CN101511359B/zh active Active
- 2007-08-30 WO PCT/EP2007/059040 patent/WO2008028860A1/en not_active Ceased
- 2007-08-30 AT AT07803049T patent/ATE543498T1/de active
- 2007-08-30 EP EP07803049A patent/EP2066319B1/en active Active
- 2007-08-30 MX MX2009002229A patent/MX2009002229A/es active IP Right Grant
- 2007-08-30 KR KR1020097004741A patent/KR101177729B1/ko active Active
- 2007-08-30 JP JP2009527118A patent/JP5325783B2/ja active Active
- 2007-08-30 AU AU2007293917A patent/AU2007293917B2/en active Active
- 2007-08-30 CA CA2662998A patent/CA2662998C/en active Active
- 2007-08-30 ES ES07803049T patent/ES2378577T3/es active Active
- 2007-08-30 BR BRPI0717035A patent/BRPI0717035B8/pt active IP Right Grant
- 2007-09-05 TW TW096133095A patent/TW200819440A/zh unknown
- 2007-09-05 CL CL200702572A patent/CL2007002572A1/es unknown
- 2007-09-06 AR ARP070103923A patent/AR062666A1/es active IP Right Grant
- 2007-09-06 PE PE2007001197A patent/PE20080659A1/es active IP Right Grant
- 2007-09-07 US US11/899,758 patent/US8962622B2/en active Active
-
2009
- 2009-02-12 IL IL197015A patent/IL197015A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ES2378577T3 (es) | 2012-04-16 |
| BRPI0717035B1 (pt) | 2021-05-04 |
| EP2066319B1 (en) | 2012-02-01 |
| US8962622B2 (en) | 2015-02-24 |
| BRPI0717035B8 (pt) | 2021-05-25 |
| JP2010502668A (ja) | 2010-01-28 |
| IL197015A (en) | 2013-12-31 |
| KR101177729B1 (ko) | 2012-09-07 |
| WO2008028860A1 (en) | 2008-03-13 |
| BRPI0717035A2 (pt) | 2014-11-25 |
| TW200819440A (en) | 2008-05-01 |
| AU2007293917A1 (en) | 2008-03-13 |
| CN101511359A (zh) | 2009-08-19 |
| CA2662998A1 (en) | 2008-03-13 |
| IL197015A0 (en) | 2009-11-18 |
| AU2007293917B2 (en) | 2013-01-31 |
| EP2066319A1 (en) | 2009-06-10 |
| US20080103142A1 (en) | 2008-05-01 |
| CL2007002572A1 (es) | 2008-04-18 |
| PE20080659A1 (es) | 2008-05-17 |
| ATE543498T1 (de) | 2012-02-15 |
| CA2662998C (en) | 2015-10-06 |
| CN101511359B (zh) | 2012-09-05 |
| JP5325783B2 (ja) | 2013-10-23 |
| MX2009002229A (es) | 2009-03-16 |
| KR20090040908A (ko) | 2009-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062666A1 (es) | Benzotriazoles como moduladores de quinasas | |
| CO6251243A2 (es) | Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c | |
| AR107912A1 (es) | Inhibidores de ret | |
| AR065863A1 (es) | Derivados de imidazolidinona | |
| AR077440A1 (es) | Bencenosulfonamidas como bloqueadores de canales de calcio y composiciones farmaceuticas | |
| AR035548A1 (es) | Compuestos organicos | |
| AR042668A1 (es) | Derivados de fosfonoxi quinazolinas y su uso farmaceutico | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| AR078609A1 (es) | 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central,tales como depresion y canceres de ovario y renales, entre otros. | |
| PE20090630A1 (es) | Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion | |
| AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
| AR067759A1 (es) | Compuestos de pirazol utiles como moduladores de la enzima raf asociada al crecimiento celular anormal | |
| AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
| AR079634A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR040031A1 (es) | Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen | |
| AR091400A2 (es) | Composicion farmaceutica que comprende derivados de sulfamida, proceso para prepararla y uso de dichos compuestos para preparar medicamentos | |
| AR056327A1 (es) | Compuestos de nucleosidos para el tratamiento de infecciones virales | |
| AR044519A1 (es) | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina | |
| AR066770A1 (es) | Derivados de piridazinona | |
| AR081932A1 (es) | Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes | |
| AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
| AR082889A1 (es) | Compuestos y composiciones para la inhibicion de nampt | |
| CO5580815A2 (es) | Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen | |
| AR085489A1 (es) | Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias | |
| PE20240886A1 (es) | Compuestos espirociclicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |